Protein / target
DNA gyrase subunit B
Protein at a glance
Biological role
ATP-dependent activity, acting on DNA
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner to maintain chromosomes in an underwound state.
View complete UniProt function annotationHide complete annotation
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner to maintain chromosomes in an underwound state (PubMed:12051842, PubMed:12051843, PubMed:1323022, PubMed:18642932, PubMed:186775, PubMed:19060136, PubMed:19965760, PubMed:20356737, PubMed:20675723, PubMed:22457353, PubMed:23294697, PubMed:23352267, PubMed:24386374, PubMed:25202966, PubMed:25849408, PubMed:3031051, PubMed:7811004, PubMed:8248233, PubMed:8621650, PubMed:9657678). This makes better substrates for topoisomerase 4 (ParC and ParE) which is the main enzyme that unlinks newly replicated chromosomes in E.coli (PubMed:9334322). Gyrase catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes (PubMed:22457352). Relaxes negatively supercoiled DNA in an ATP-independent manner (PubMed:337300). E.coli gyrase has higher supercoiling activity than other characterized bacterial gyrases; at comparable concentrations E.coli gyrase introduces more supercoils faster than M.tuberculosis gyrase, while M.tuberculosis gyrase has higher decatenation than supercoiling activity compared to E.coli (PubMed:22457352). E.coli makes 15% more negative supercoils in pBR322 plasmid DNA than S.typhimurium; the S.typhimurium GyrB subunit is toxic in E.coli, while the E.coli copy can be expressed in S.typhimurium even though the 2 subunits have 777/804 residues identical (PubMed:17400739). The enzymatic differences between E.coli gyrase and topoisomerase IV are largely due to the GyrA C-terminal domain (approximately residues 524-841) and specifically the GyrA-box (PubMed:16332690, PubMed:8962066)
Subcellular location
Domains and Gene Ontology detail (16)Hide
Domains & features
Gene Ontology
- Cchromosome
- Ccytoplasm
- Ccytosol
- CDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex
- FATP binding
- FATP-dependent activity, acting on DNA
- FDNA binding
- FDNA negative supercoiling activity
- FDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
- Fmetal ion binding
- PDNA topological change
- PDNA-templated DNA replication
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Bacterial DNA gyrase inhibitor
Indicated for Acne Vulgaris, Bacterial Infections, Corneal Ulcer, Eye Infections
Bacterial DNA gyrase inhibitor
Indicated for Bacterial Infections, Eye Infections, Gonorrhea, Infections
Bacterial DNA gyrase inhibitor
Indicated for Bacterial Infections, Eye Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076794)
- New publicationGlobal diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Safety communication
Drug Safety Update: Norfloxacin: restricted use in urinary infections
- New publicationCefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.
- New publicationComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
- New publicationProphylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.